Phase IV Commitments Increasingly Delayed in 2007, FDA Report Finds

Displaying a trend policy-makers hope to reverse through provisions in the FDA Amendments Act, FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Post-marketing Commitment Studies" shows that the rate of delayed post-marketing commitments in 2007 has again slightly increased